|Items||Size （2mg）||Size（5mg X 2）|
|Particle size||2 μm||2 μm|
|Physical appearance||Powder mixture||Powder mixture|
|Amount of Coupled Protein||>702pmol (20μg) Spike RBD protein/mg beads||>702 pmol (20μg) Spike RBD protein/mg beads|
|Binding Capacity||>200 pmol (15μg) Anti-S1-SCT-ic1 Ab/mg beads||>200 pmol (15μg) Anti-S1-SCT-ic1 Ab/mg beads|
|Formulation||PBS, pH 7.4, with 10% Trehalose||PBS, pH 7.4, with 10% Trehalose|
|Reconstitution||2 mL ultrapure water (1 mg beads/mL)||5 mL ultrapure water (1 mg beads/mL)|
Upon receipt, please store the beads at -20℃ for 1 year in lyophilized state.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
1. Resuspend the lyophilized beads by adding the buffer of choice.
2. Add analyte to the suspension, mix and incubate to enable specific binding of the beads and the target protein.
3. Magnetize beads, remove supernatant, and wash unbound protein fractions to capture target protein-bound beads.
4. Wash, magnetize the beads and collect purified target protein for use in downstream applications.
Immobilized 29.8 μg Spike RBD protein/1mg beads can bind the Anti-S1 Antibody (Cat.No.S1N-M122) with an EC50 of 0.05449 μg/mL (QC tested).
Accelerated stability test. After placing the lyophilized beads at 37℃ for 7 days, binding activity between the SARS-CoV-2 (Omicron) Spike RBD-coupled Magnetic Beads (Cat.No. MBS-K043) and Mouse,Anti-S1 showed little deviation from the unaccelerated sample (%RSD<15%). Data were measured on day 0, 3, 7 respectively.
Freeze-thaw stability test. After different freeze-thaw cycles, binding activity between the SARS-CoV-2 (Omicron) Spike RBD-coupled Magnetic Beads (Cat.No. MBS-K043) and Mouse,Anti-S1 showed little deviation from the unfreeze-thaw sample (%RSD<10%). Three freeze-thaw cycles were performed.
Price(USD) : $800.00
Price(USD) : $2500.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.